4　その他

⑴　契約手続において使用する言語及び通貨　日本語及び日本国通貨。

⑵　入札保証金及び契約保証金　免除

⑶　入札者に要求される事項　この一般競争に参加を希望する者は、封印した入札書に本公告に示した物品を納入できることを証明する書類を添付して入札書の受領期限までに提出しなければならない。入札者は、開札日の前日までの間において、学長から当該書類に関し説明を求められた場合は、それに応じなければならない。

⑷　入札の無効　本公告に示した競争参加資格のない者の提出した入札書、入札者に求められる義務を履行しなかった者の提出した入札書、その他入札説明書による。

⑸　契約書作成の要否　要

⑹　落札者の決定方法　本公告に示した物品を納入できると学長が判断した入札者であって、旭川医科大学契約細則第13条の規定に基づいて作成された予定価格の制限の範囲内で最低価格をもって有効な入札を行った入札者を落札者とする。

⑺　手続における交渉の有無　無

⑻　その他　詳細は、入札説明書による。なお、入札説明書等で当該調達に関する環境上の条件を定めた調達であると示されている場合は、十分理解した上で応札すること。

5　Summary

⑴　Official in charge of disbursement of the procuring entity : Yuji Nishikawa, President, Asahikawa Medical University

⑵　Classification of the products to be procured : 4

⑶　Nature and quantity of the products to be purchased :

A　Durvalumab (Genetical Recombination) (500 ㎎／10 mL／1 vial) 525 vials

B　Palivizumab (Genetical Recombination) (100 ㎎／1 mL／1 vial) 264 vials

C　Fulvestrant (250 ㎎／5 mL／2 syringes／1 case) 831 cases

D　Epcoritamab (Genetical Recombination) (48 ㎎／0.8 mL／1 vial) 30 vials

E　Risankizumab (Genetical Recombination) (75 ㎎／0.83 mL／1 syringe) 346 syringes

F　Risankizumab (Genetical Recombination) (360 ㎎／2.4 mL／1 kit) 84 kits

G　Ravulizumab (Genetical Recombination) (300 ㎎／3 mL／1 vial) 60 vials

H　Eribulin Mesilate (1.0 ㎎／1 vial) 451 vials

I　Remdesivir (100 ㎎／1 vial) 569 vials

J　Mepolizumab (Genetical Recombination) (100 ㎎／1 mL／1 kit) 308 kits

K　Botulinum Toxin Type A (100 units／1 vial) 396 vials

L　Avalglucosidase Alfa (Genetical Recombination) (103 ㎎／1 vial) 234 vials

M　Canakinumab (Genetical Recombination) (150 ㎎／1 vial) 176 vials

N　Ruxolitinib Phosphate (6.60 ㎎／20 tablets／1 case) 246 cases

O　Onasemnogene abeparvovec (1 set) 1 set

P　Brolucizumab (Genetical Recombination) (19.8 ㎎／0.165 mL／1 kit) 352 kits

Q　Nusinersen Sodium (12.63 ㎎／5 mL／1 vial) 2 vials

R　Pomalidomide (4 ㎎／7 capsules／1 case) 223 cases

S　Cetuximab (Genetical Recombination) (100 ㎎／20 mL／1 vial) 1521 vials

T　Avelumab (Genetical Recombination) (200 ㎎／1 vial) 677 vials

U　Daratumumab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) (1800 ㎎／15 mL／1 vial・30000 units／15 mL／1 vial) 225 vials

V　Pegfilgrastim (Genetical Recombination) (3.6 ㎎／0.36 mL／1 syringe) 376 syringes

W　Romiplostim (Genetical Recombination) (375 ㎍／1 vial) 324 vials

X　Aflibercept (Genetical Recombination) (30.1 ㎎／0.263 mL／1 syringe) 209 syringes

Y　Nivolumab (Genetical Recombination) (20 ㎎／2 mL／1 vial) 856 vials

Z　Nivolumab (Genetical Recombination) (240 ㎎／24 mL／1 vial) 946 vials

AA　Dinutuximab (Genetical Recombination) (17.5 ㎎／5 mL／1 vial) 24 vials

AB　Paclitaxel (100 ㎎／1 vial) 718 vials

AC　Guselkumab (Genetical Recombination) (100 ㎎／1 mL／1 syringe) 164 syringes

AD　Trastuzumab Deruxtecan (Genetical Recombination) (107 ㎎／1 vial) 1074 vials

AE　Denosumab (Genetical Recombination) (120 ㎎／1.7 mL／1 vial) 894 vials

AF　Bevacizumab (Genetical Recombination) (400 ㎎／16 mL／1 vial) 432 vials

AG　Satralizumab (Genetical Recombination) (120 ㎎／1 mL／1 syringe) 94 syringes

AH　Atezolizumab (Genetical Recombination) (1200 ㎎／20 mL／1 vial) 338 vials

AI　Faricimab (Genetical Recombination) (28.8 ㎎／0.24 mL／1 vial) 268 vials

AJ　Pertuzumab (Genetical Recombination)・Trastuzumab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) (600 ㎎／10 mL／1 vial・600 ㎎／10 mL／1 vial・20000 units／10 mL／1 vial) 376 vials

AK　Polatuzumab Vedotin (Genetical Recombination) (38 ㎎／1 vial) 453 vials

AL　Inebilizumab (Genetical Recombination) (100 ㎎／10 mL／3 vials／1 case) 2 cases

AM　Golimumab (Genetical Recombination) (50 ㎎／0.5 mL／1 syringe) 222 syringes

AN　Ustekinumab (Genetical Recombination) (45 ㎎／0.5 mL／1 syringe) 701 syringes

AO　Infliximab (Genetical Recombination) (100 ㎎／1 vial) 980 vials

AP　Ramucirumab (Genetical Recombination) (500 ㎎／50 mL／1 vial) 198 vials

AQ　Ixekizumab (Genetical Recombination) (80 ㎎／1 syringe／1 kit) 208 kits

AR　Brentuximab Vedotin (Genetical Recombination) (55 ㎎／1 vial) 74 vials

AS　Vedolizumab (Genetical Recombination) (331.2 ㎎／1 vial) 80 vials

AT　Vosoritide (Genetical Recombination) (0.56 ㎎／1 vial) 371 vials

AU　Pembrolizumab (Genetical Recombination) (100 ㎎／4 mL／1 vial) 2126 vials

AV　SAPIEN 3 Ultra RESILIA System (S3URCM23J 23 ㎜ for Aortic valve) or its equivalent 12 sets

AW　SAPIEN 3 Ultra RESILIA System (S3URCM26J 26 ㎜ for Aortic valve) or its equivalent 4 sets

AX　SOUNDSTAR eco Catheter (10439236　8 Fr 90 ㎝ for GE Healthcare) or its equivalent 108 pieces

AY　THERMOCOOL SMARTTOUCH SF Catheter (D134805　7.5 Fr 115 ㎝ Tip Electrode 3.5 ㎜ Curve Type DF) or its equivalent 118 pieces

AZ　ACUNAV (10135910　8 Fr 90 ㎝) or its equivalent 66 pieces

BA　OCTARAY (D160903　7.5 Fr 113 ㎝ 48＋4 poles Spacing 3―3―3―3―3 ㎜) or its equivalent 88 pieces

BB　SURGIFLO (5094　8 ml (8g)) or its equivalent 207 pieces

BC　HeartMate3 LVAD (80―580) or its equivalent 1 set

BD　EVAHEART2 LVAD (C02＋BP310) or its equivalent 1 set

BE　Impella CP SmartAssist Set (0048―0024-JP) or its equivalent 15 sets

BF　Arctic Front Advance Cardiac Cryo-Ablation Catheter (AFAPRO28　10.5 Fr Lg140 ㎝ Balloon Diameter 28 ㎜ 45° Curve) or its equivalent 34 pieces

BG　Cobalt XT HF Quad CRT-D MRI (DTPA2QQ IS4／DF4) or its equivalent 8 pieces

BH　Evolut FX (EVOLUTFX-26　26 ㎜ Valve ring 20―23 ㎜) or its equivalent 18 sets

BI　Evolut FX (EVOLUTFX-29　29 ㎜ Valve ring 23 ―26 ㎜) or its equivalent 6 sets

BJ　BeeAT (S208282-SAOC 6 Fr 80 ㎝ 20 poles) or its equivalent 128 pieces